Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response

被引:6
|
作者
Gu, Tianwei [1 ]
Hong, Ting [1 ]
Zhang, Pengzi [1 ]
Tang, Sunyinyan [1 ]
Bi, Yan [1 ]
Lu, Hai [2 ]
Men, Lichuang [2 ]
Ma, Dongwei [2 ]
Zhu, Dalong [1 ]
机构
[1] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Sanofi Investment Co Ltd, Shanghai, Peoples R China
关键词
Asia; Basal insulin; China; Dose titration; Insulin glargine 100 U/mL; Nomogram; Pooled analysis; Type 2 diabetes mellitus; BODY-MASS INDEX; BASAL INSULIN; OBSERVATIONAL REGISTRY; PREMIXED INSULIN; TREATMENT ORBIT; UNITED-STATES; NPH INSULIN; TITRATION; THERAPY; TARGET;
D O I
10.1007/s13300-018-0381-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In Asia, patients with type 2 diabetes mellitus (T2DM) often have suboptimal glycemic control for many years prior to initiating basal insulin. Active titration of basal insulin is also required to improve glycemic outcomes. This pooled analysis was conducted to determine the impact of patient baseline covariates on the required dose of basal insulin and treatment response, for the improved management of Asian patients with T2DM. Methods: Data on insulin-naive Asian patients with T2DM who initiated and fully titrated insulin glargine 100 U/mL (Gla-100) for >= 20 weeks were pooled from seven randomized, controlled, treat-to-target trials. Covariance and multivariate linear/logistic regression analyses were applied to determine the impact of the baseline covariates on Gla-100 dose (primary outcome) and treatment response (secondary outcomes) at week 24 for patients from Asia (N = 724) and from China alone (n = 249). Based on the multivariate analysis for the primary outcome in the Asian population, a nomogram was developed. Results: The dose of Gla-100 at week 24 was negatively correlated with age and positively correlated with body mass index (BMI) and fasting plasma glucose (FPG) at baseline in both Asian and Chinese populations. In both populations, higher baseline glycated hemoglobin (HbA(1c)) was associated with a lower reduction in HbA1c from baseline, higher HbA(1c) at week 24, and a lower chance of achieving HbA(1c) < 7% at week 24. The constructed nomogram enables calculation of the likely dose of Gla-100 required by Asian patients with T2DM to achieve HbA(1c) < 7% at week 24. Conclusions: Higher doses of Gla-100 are likely to be required in younger patients or patients with higher baseline BMI or FPG. The nomogram developed in this study can aid clinicians to titrate the dose of Gla-100 appropriately. Evidence in this pooled analysis also indicates that initiating basal insulin at a lower HbA(1c) can lead to greater glycemic control.
引用
收藏
页码:771 / 787
页数:17
相关论文
共 50 条
  • [41] Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
    Baser, Onur
    Tangirala, Krishna
    Wei, Wenhui
    Xie, Lin
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 497 - 505
  • [42] More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naive patients with type 2 diabetes mellitus
    Polonsky, W.
    Traylor, L.
    Wei, W.
    Shi, R.
    Ameer, B.
    Vlajnic, A.
    Nicolucci, A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03) : 255 - 261
  • [43] Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes Mellitus
    Chen, Jieling
    Nair, Radhika
    Siadaty, Mir
    Brown, Katelyn
    Meah, Yunus
    Taylor, April Dawn
    He, Xuanyao
    Fan, Ludi
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (07) : 839 - +
  • [44] New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Ziemen, M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04) : 386 - 394
  • [45] Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study
    Zhang, Bo
    Zhao, Jing
    Yang, Wenying
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (03)
  • [46] Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes -: a simulation with the Diabetes Mellitus Model (DMM)
    Janka, H. U.
    Hessel, F.
    Walzer, S.
    Mueller, E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (12) : 623 - 630
  • [47] Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes
    Ying Zhang
    Yi-juan Xie
    Dong-dong Meng
    Hao-hang Zhang
    Hui Chen
    En Liu
    Diabetology & Metabolic Syndrome, 6
  • [48] Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis
    Men, Peng
    Qu, Shuli
    Song, Zhenqiang
    Liu, Yanjun
    Li, Chaoyun
    Zhai, Suodi
    DIABETES THERAPY, 2020, 11 (08) : 1745 - 1755
  • [49] Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis
    Chaudhuri, Ajay
    Rosenstock, Julio
    DiGenio, Andres
    Meneghini, Luigi
    Hollander, Priscilla
    McGill, Janet B.
    Dandona, Paresh
    Ilgenfritz, John
    Riddle, Matthew
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 (03) : 258 - 267
  • [50] Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials
    Sun, Di
    Zhang, Xu
    Hou, Xiu-xin
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (09) : 622 - 627